SAVA

MKT CAP:$115M

Cassava Sciences, Inc.

Market Cap

$115M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.62-$0.47 (-22.49%)

Apr 13, 2026

Company Details

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and inves...

CEO

Richard Jon Barry

IPO Date

Jul 14, 2000

Website

www.cassavasciences.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$91M

EPS (Diluted)

-$1.88

Free Cash Flow

-$33M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 12, 2026

$0EPS -$1.88

Q4 2025

Mar 12, 2026

$0EPS -$0.26

Q3 2025

Nov 12, 2025

$0EPS -$0.22

Q2 2025

Aug 14, 2025

$0EPS -$0.92

Q1 2025

May 8, 2025

$0EPS -$0.48

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$15M	-$18M
Q2 22	$0	-$17M	-$20M
Q3 22	$0	-$19M	-$21M
Q4 22	$0	-$18M	-$21M
Q1 23	$0	-$22M	-$27M
Q2 23	$0	-$392.0K	-$29M
Q3 23	$0	-$24M	-$28M
Q4 23	$0	-$19M	-$23M
Q1 24	$0	-$16M	-$20M
Q2 24	$0	-$15M	-$61M
Q3 24	$0	-$18M	-$31M
Q4 24	$0	-$21M	-$29M
Q1 25	$0	-$14M	-$25M
Q2 25	$0	-$5M	-$45M
Q3 25	$0	-$200.0K	-$12M
Q4 25	$0	$19M	-$14M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$24M	-$24M
Q2 22	-$11M	-$13M
Q3 22	-$22M	-$23M
Q4 22	-$21M	-$21M
Q1 23	-$13M	-$14M
Q2 23	-$20M	-$20M
Q3 23	-$27M	-$27M
Q4 23	-$22M	-$22M
Q1 24	-$19M	-$19M
Q2 24	-$18M	-$18M
Q3 24	-$18M	-$18M
Q4 24	-$61M	-$61M
Q1 25	-$11M	-$11M
Q2 25	-$5M	-$5M
Q3 25	-$6M	-$6M
Q4 25	-$10M	-$10M

Capital Expenditures

Quarter	CapEx
Q1 22	$425.0K
Q2 22	$1M
Q3 22	$1M
Q4 22	$335.0K
Q1 23	$357.0K
Q2 23	$6.0K
Q3 23	$22.0K
Q4 23	$41.0K
Q1 24	$0
Q2 24	$29.0K
Q3 24	$17.0K
Q4 24	$57.0K
Q1 25	$0
Q2 25	$0
Q3 25	$80.0K
Q4 25	$501.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+404.4%
Q2 22	—	+287.6%
Q3 22	—	+118.9%
Q4 22	—	+45.0%
Q1 23	—	+48.8%
Q2 23	—	+44.5%
Q3 23	—	+30.6%
Q4 23	—	+8.8%
Q1 24	—	-24.8%
Q2 24	—	+113.4%
Q3 24	—	+9.8%
Q4 24	—	+29.4%
Q1 25	—	+23.3%
Q2 25	—	-26.1%
Q3 25	—	-61.3%
Q4 25	—	-54.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$495.0K	—
Q2 22	$485.0K	—
Q3 22	$470.0K	—
Q4 22	$616.0K	—
Q1 23	$673.0K	—
Q2 23	$835.0K	—
Q3 23	$949.0K	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$0	—
Q3 24	$6M	—
Q4 24	$6M	—
Q1 25	$5M	—
Q2 25	$5M	—
Q3 25	$4M	—
Q4 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$15M	$3M	—
Q2 22	$17M	$3M	—
Q3 22	$19M	$3M	—
Q4 22	$19M	$3M	—
Q1 23	$22M	$4M	—
Q2 23	$25M	$4M	—
Q3 23	$24M	$4M	—
Q4 23	$19M	$4M	—
Q1 24	$16M	$7M	—
Q2 24	$15M	$52M	—
Q3 24	$18M	$14M	—
Q4 24	$21M	$943.0K	—
Q1 25	$14M	$8M	—
Q2 25	$5M	$9M	—
Q3 25	$4M	—	$8M
Q4 25	$4M	$52M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$210M	$0	$210M
Q2 22	$197M	$0	$197M
Q3 22	$175M	$0	$175M
Q4 22	$201M	$0	$201M
Q1 23	$187M	$0	$187M
Q2 23	$168M	$0	$168M
Q3 23	$142M	$0	$142M
Q4 23	$121M	$0	$121M
Q1 24	$124M	$0	$124M
Q2 24	$207M	$0	$207M
Q3 24	$149M	$0	$149M
Q4 24	$129M	$0	$129M
Q1 25	$117M	$0	$117M
Q2 25	$112M	$0	$112M
Q3 25	$106M	$0	$106M
Q4 25	$96M	$0	$96M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	40M	+0.0%	+5.9%
Q2 22	40M	+0.1%	+0.2%
Q3 22	40M	+0.1%	+0.2%
Q4 22	41M	+1.8%	+2.0%
Q1 23	42M	+2.4%	+4.4%
Q2 23	42M	+0.1%	+4.4%
Q3 23	42M	+0.5%	+4.9%
Q4 23	42M	+0.4%	+3.5%
Q1 24	44M	+4.5%	+5.7%
Q2 24	46M	+4.8%	+10.5%
Q3 24	48M	+3.8%	+14.2%
Q4 24	48M	+0.3%	+14.0%
Q1 25	48M	+0.3%	+9.4%
Q2 25	48M	+0.1%	+4.6%
Q3 25	48M	-0.0%	+0.7%
Q4 25	48M	+0.0%	+0.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	24
Q2 22	$0	24
Q3 22	$0	24
Q4 22	$0	26
Q1 23	$0	26
Q2 23	$0	26
Q3 23	$0	26
Q4 23	$0	29
Q1 24	$0	29
Q2 24	$0	29
Q3 24	$0	29
Q4 24	$0	30
Q1 25	$0	30
Q2 25	$0	30
Q3 25	$0	30
Q4 25	$0	50K

Revenue / Employee